Navigation Links
Misonix Expands Sales Organization for Direct Sales of the SonicOne(TM) Wound Management System and the SonaStar(R) Ultrasonic Surgical Aspirator in the United States
Date:9/1/2009

FARMINGDALE, N.Y., Sept. 1 /PRNewswire-FirstCall/ -- Misonix, Inc., (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, today announced the second expansion of its direct sales channel for the United States, which was first disclosed in June 2008. In addition to its already established, commission based, contract sales organization, the Company has added 5 experienced, highly trained Region Managers. The Region Managers will support the efforts of the contract sales representatives and will sell Misonix labeled product directly to hospitals and clinics in key markets; including, California, Texas, New York, Florida, and Illinois. In addition to the SonicOne(TM) Wound Management System, which the domestic sales team began to sell in the latter part of calendar 2008, direct to hospital sales of the SonaStar(R) Ultrasonic Surgical Aspirator have now begun. Aesculap, Inc., a division of B. Braun, the German conglomerate, who has sold SonaStar exclusively in the United States in the past, continues to market SonaStar on a non-exclusive basis.

The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels. In addition, OsteoSculpt(TM) bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.

"We are confident that by expanding our domestic sales organization we can grow our revenue in the United States," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "This sales group is designed to increase market penetration and increase revenue for these important products while building customer awareness and brand equity for Misonix. Additionally, we believe this sales team, which is very experienced in the sale of medical equipment and disposables, will provide us with the capability to effectively sell other Misonix labeled products to US clinical customers in the years to come."

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

    Investor Relations Contact:
    Kevin McGrath
    Cameron Associates
    212-245-4577
    Kevin@cameronassoc.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Misonix Announces the Sale of Its Labcaire Business for up to $5.6 Million
2. Misonix Receives First Award for Forensic Equipment in China
3. Misonix Announces Participation in 2nd International Workshop on Focal Therapy
4. Misonix Subsidiary, Sonora Medical Systems, Achieves ISO 17025 Accreditation
5. Misonix Announces the Purchase of Patents From ProRhythm, Inc.
6. Misonix Announces Attendance at 22nd Annual Symposium on Advanced Wound Care
7. Misonix Announces Participation in Annual Diabetic Foot Global Conference
8. Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009
9. Misonix Announces New HIFU Distribution Agreement For Portugal
10. Misonix Announces New HIFU Distribution Agreement for Romania and Bulgaria
11. Misonix Announces New Distribution Agreement for Portugal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... The new knee compression sleeves ... to buy neoprene knee sleeves for lifting and any sport that requires ... on two main aspects to provide a higher quality knee sleeve performance. Firstly it ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... today that they have teamed up with The American College of Surgeons (ACS) ... ACS’s Committee on Trauma, the “Bleeding Control Basic” course is a pilot program ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... and many more tools allowing FCPX editors to create professional looking video in ... , Perfect Harmony contains a beautifully designed 3D environment for placing in ...
(Date:12/4/2016)... ... December 04, 2016 , ... "Pro3rd Displace ... animation styles with unique displacement design elements," said Christina Austin - CEO of ... Choose from a variety of design styles that include both left aligned and ...
(Date:12/2/2016)... ... 2016 , ... Halfway through its partnership with First 5 LA, Western University ... than 15,900 children 5 years old and younger and treatment services to more than ... of five years to Western University of Health Sciences, UCLA and USC, beginning March ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)...  Wellbridge Health and Gateway Health proudly announce a dynamic ... and Medicaid plan members with specific high risk needs. ... of this group of consumers, Wellbridge combines technology and population ... insight into members, daily behaviors and lifestyle. ... , , ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 ... today announced preliminary safety and efficacy data from ... oral selective MDM2 inhibitor, suggesting that DS-3032 may ... relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic ... part of the phase 1 study of DS-3032 were ...
(Date:12/5/2016)... 2016 Eisai Inc. announced today new analyses ... Meeting of the American Epilepsy Society (AES). ... an adjunctive therapy for the treatment of partial onset ... primary generalized tonic-clonic seizures (PGTC) in patients with epilepsy ... see Important Safety Information for FYCOMPA, including Boxed WARNING ...
Breaking Medicine Technology: